Have a personal or library account? Click to login
Current status and future prospects of drug eluting stents for restenosis / Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove Cover

Current status and future prospects of drug eluting stents for restenosis / Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove

Acta Pharmaceutica
Volume 62 (2012): Issue 4 (December 2012)
By: Maulik J. Patel,  Sanjay S. Patel,  Nidhi S. Patel and  Natvarlal M. Patel  
Open Access
|Jan 2013

References

  1. 1. E. Sousa, P. Serruys and M. Costa, New frontiers in cardiology: drug-eluting stents: Part I, Circulation 107 (2003) 2274-2279; DOI: 10.1161/01.CIR.0000069330.41022.90.10.1161/01.CIR.0000069330.41022.90
    Search in Google Scholar
  2. 2. E. Edelman and C. Rogers, Pathobiologic responses to stenting, Am. J. Cardiol. 81 (1998) 4E-6E; DOI: 10.1016/S0002-9149(98)00189-1.10.1016/S0002-9149(98)00189-1
    Search in Google Scholar
  3. 3. P. Serruys, B. Strauss and H. Van Beusekom, Stenting of coronary arteries: has a modern Pandora’s Box been opened? J. Am. Coll Cardiol. 17 (1991) 143B-154B; DOI: 10.1016/0735-1097(91)90951-5.10.1016/0735-1097(91)90951-5
    Search in Google Scholar
  4. 4. M. Costa, D. Foley and P. Serruys, Restenosis: the Problem and How to Deal With It, in Practical Interventional Cardiology (Eds. E. Grech and D. Ramsdale), 2nd ed., Martin Dumitz, London 2002, pp. 279-294.
    Search in Google Scholar
  5. 5. D. Whelan, H. Van Beusekom and W. Van der Giessen, Mechanisms of drug loading and release kinetics, Semin. Interv. Cardiol. 3 (1998) 127-131.
    Search in Google Scholar
  6. 6. W. Van der Giessen, A. Lincoff and R. Schwartz, Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries, Circulation 94 (1996) 1690-1697; DOI: 10.1161/01.CIR.94.7.1690.10.1161/01.CIR.94.7.1690
    Search in Google Scholar
  7. 7. D. Drachman, E. Edelman and P. Seifert, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months, J. Am. Coll. Cardiol. 36 (2000) 2325-2332; DOI: 10.1016/S0735-1097(00)01020-2.10.1016/S0735-1097(00)01020-2
    Search in Google Scholar
  8. 8. B. Ratner, The blood compatibility catastrophe, J. Biomed. Mater. Res. 27 (1993) 283-287; DOI: 10.5897/AJPP11.107.10.5897/AJPP11.107
    Search in Google Scholar
  9. 9. M. Lovich, C. Creel and K. Hong, Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel, J. Pharm. Sci. 90 (2001) 1324-1335; DOI: 10.1002/JPS.1085.10.1002/jps.1085
    Search in Google Scholar
  10. 10. R. Braun-Dullaeus, M. Mann and V. Dzau, Cell cycle progression: new therapeutic target for vascular proliferative disease, Circulation 98 (1998) 82-89; DOI: 10.1161/01.CIR.98.1.82.10.1161/01.CIR.98.1.82
    Search in Google Scholar
  11. 11. C. Morton Allison, D. Crossman and J. Gunn, The influence of physical stent parameters upon restenosis, Pathol. Biol. 52 (2004) 196-205; DOI: 10.1016/J.PATBIO.2004.03.013.10.1016/j.patbio.2004.03.013
    Search in Google Scholar
  12. 12. C. Rogers, Optimal stent design for drug delivery, Rev. Cardiovasc. Med. 5 (2004) S9-S15.
    Search in Google Scholar
  13. 13. K. Lau, A. Johan, U. Sigwart and J. Hung, A stent is not just a stent: stent construction and design do matter in its clinical performance, Singapore Med. J. 45 (2004) 305-312.
    Search in Google Scholar
  14. 14. A. Colombo, G. Stankovic and J. W. Moses, Selection of coronary stents, J. Am. Coll. Cardiol. 40 (2002) 1021-1033.10.1016/S0735-1097(02)02123-X
    Search in Google Scholar
  15. 15. D. Stoeckel, C. Bonsignore and S. Duda, A survey of stent designs, Minim. Invasive Ther. Allied Technol. 11 (2002) 137-147.10.1080/136457002760273340
    Search in Google Scholar
  16. 16. L. Lim, Biocompatability of stent materials, MIT Undergrad. Res. J. 11 (2004) 33-37.
    Search in Google Scholar
  17. 17. J. Bier, P. Zalesky and S. Li, A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics, J. Interven. Cardiol. 5 (1992) 187-194.
    Search in Google Scholar
  18. 18. B. Berk, J. Gordon and R. Alexander, Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty, J. Am. Coll. Cardiol. 17 (1991) 111B-117B; DOI: 10.1016/0735-1097(91)90946-7.10.1016/0735-1097(91)90946-7
    Search in Google Scholar
  19. 19. C. Pepine, J. Hirshfeld and R. Macdonald, A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty, M-HEART Group Circ. 81 (1990) 1753-1761; DOI: 10.1161/01.CIR.81.6.1753.10.1161/01.CIR.81.6.1753
    Search in Google Scholar
  20. 20. I. De Scheerder, K. Wang and K. Wilczek, Local methylprednisolone inhibition of foreign body response to coated intracoronary stents, Coron. Artery. Dis. 7 (1996) 161-166.10.1097/00019501-199602000-00011
    Search in Google Scholar
  21. 21. A. M. Lincoff, J. G. Furst and S. G. Ellis, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model, J. Am. Coll. Cardiol. 29 (1997) 808-816; DOI: 10.1016/S0735-1097(96)00584-0.10.1016/S0735-1097(96)00584-0
    Search in Google Scholar
  22. 22. D. Holmes, M. Savage and J. LaBlanche, Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial, Circulation 106 (2002) 1243-1250. DOI: 10.1161/01.CIR.0000028335.31300DA.
    Search in Google Scholar
  23. 23. A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott and R. Virmani, Oral everolimus inhibits in-stent neointimal growth, Circulation 106 (2002) 2379-2384; DOI: 10.1161/01.CIR.0000033973.06059.04.10.1161/01.CIR.0000033973.06059.04
    Search in Google Scholar
  24. 24. P. B. Schiff and S. B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells, Proc. Natl. Acad. Sci. USA 77 (1980) 1561-1565.10.1073/pnas.77.3.1561
    Search in Google Scholar
  25. 25. P. W. Serruys, Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis, Circulation 92 (1995) 2759-2760.
    Search in Google Scholar
  26. 26. R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono and A. H. Gershlick, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody, Circulation 94 (1996) 3311-3317; DOI: 10.1161/01.CIR.94.12.3311.10.1161/01.CIR.94.12.3311
    Search in Google Scholar
  27. 27. C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell and Y. L. Tran, Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor, J. Am. Coll. Cardiol. 39 (2002) 1852-1858; DOI: 10.1016/S0735-1097(02)01873-9.10.1016/S0735-1097(02)01873-9
    Search in Google Scholar
  28. 28. C. Rogers, S. Parikh, P. Seifert and E. R. Edelman, Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair, Circulation 94 (1996) 2909-2914; DOI: 10.1161/01.CIR.94.11.2909.10.1161/01.CIR.94.11.29098941120
    Search in Google Scholar
  29. 29. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: The healing-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry, J. Am. Coll. Cardiol. 45 (2005) 1574-1579.
    Search in Google Scholar
  30. 30. D. J. Cohen, Economics of coronary restenosis: implications of drug-eluting stents, http://www.tctmd.com/show.aspx?id=58808; last access: April 22, 2012
    Search in Google Scholar
  31. 31. P. W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne, J. Belardi, U. Sigwart, A. Colombo, J. J. Gay, P. Henvel, J. Delcan and M. Morel, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease, New Engl. J. Med. 331 (1994) 489-495; DOI: 10.10.1056/NEJM199408253310801.10.1056/NEJM199408253310801
    Search in Google Scholar
  32. 32. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. Motohara and H. Uehata, Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans, Circulation 102 (2000) 399-404; DOI: 10.1161/01.CIR.102.4.399.10.1161/01.CIR.102.4.399
    Search in Google Scholar
  33. 33. J. A. Ormiston, P. W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. W. Webster, Y. Onuma, H. M. Garcia-Garcia, R. McGreevy and S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet 371 (2008) 899-907; DOI: 10.1016/S0140-6736(08)60415-8.10.1016/S0140-6736(08)60415-8
    Search in Google Scholar
  34. 34. J. A. Ormiston and P. W. Serruys, Bioabsorbable coronary stents, Circ. Cardiovasc. Interv. 2 (2009) 255-260; DOI: 10.1161/CIRCINTERVENTIONS.109.859173.10.1161/CIRCINTERVENTIONS.109.859173
    Search in Google Scholar
  35. 35. S. Ramcharitar and P. W. Serruys, Fully biodegradable coronary stents: progress to date, Am. J. Cardiovasc. Drugs 8 (2008) 305-314.10.2165/00129784-200808050-00003
    Search in Google Scholar
  36. 36. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman and R. Waksman, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial, Lancet 369 (2007) 1869-1875; DOI: 10.1016/S0140-6736(07)60853-8.10.1016/S0140-6736(07)60853-8
    Search in Google Scholar
  37. 37. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S. H. Su, J. Shulze and S. Kar, Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model, Circ. Cardiovasc. Interv. 3 (2010) 174-183; DOI: 10.1161/CIRCINTERVENTIONS.109.87522.
    Search in Google Scholar
  38. 38. J. R. Costa, Jr., A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, G. Maldonado, R. Staico, D. Siqueira, A. G. Sousa, R. Bonan and J. E. Sousa, 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial, JACC Cardiovasc. Interv. 2 (2009) 422-427; DOI: 10.1016/j.jcin.2009.02.009.10.1016/j.jcin.2009.02.00919463465
    Search in Google Scholar
  39. 39. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. L. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry, J. Am. Coll. Cardiol. 45 (2005) 1574-1579; DOI: 10.1016/j.jacc.2005.01.048.10.1016/j.jacc.2005.01.04815893169
    Search in Google Scholar
  40. 40. H. J. Duckers, S. Silber, R. D. Winter, P. D. Heijer, B. Rensing and M. Rau, Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent, EuroIntervention 3 (2007) 67-75.
    Search in Google Scholar
  41. 41. M. Co, E. Tay, C. H. Lee, K. K Poh, A. Low and J. Lim, Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up, Am. Heart. J. 155 (2008) 128-132; DOI: 10.1016/j.ahj.2007.08.031.10.1016/j.ahj.2007.08.03118082503
    Search in Google Scholar
  42. 42. A. Abizaid and J. R. Costa, Jr., New drug-eluting stents: An overview on biodegradable and polymer-free next-generation stent system, Circ. Cardiovasc. Interv. 3 (2010) 384-393; DOI: 10.1161/CIRCINTERVENTIONS.109.891192.10.1161/CIRCINTERVENTIONS.109.89119220716758
    Search in Google Scholar
  43. 43. C. Lovadahl, J. Thyber and A. Hultgardh-Nilsson, The synthetic metalloproteinase inhibitor batimastat suppresses injury induced phosphorylation of MAP kinase ERK/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro, J. Vasc. Res. 37 (2000) 345-354; DOI: 10.1159/000025750.10.1159/00002575011025397
    Search in Google Scholar
  44. 44. P. W. Serruys, S. Garg, A. Abizaid, J. Ormiston, S. Windecker, S. Verheye, C. Dubois, J. Stewart, K. E. Hauptmann, J. Schofer, K. Stangl, B. Witzenbichler, M. Wiemer, E. Barbato, T. de Vries, A. M. den Drijver, H. Otake, L. Meredith, S. Toyloy and P. Fitzgerald, A randomised comparison of novolimus-eluting and zotarolimus eluting coronary stents: 9-month follow-up results of the EXCELLA II study, EuroIntervention 6 (2010) 195-205.
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10007-012-0036-8 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 473 - 496
Published on: Jan 15, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
drug eluting stent,
restenosis,
biodegradable polymer
Related subjects:
Pharmacy,
Pharmacy, other

© 2013 Maulik J. Patel, Sanjay S. Patel, Nidhi S. Patel, Natvarlal M. Patel, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Previous articleVolume 62 (2012): Issue 4 (December 2012)Next article